Kyverna Therapeutics Reports Q3 GAAP EPS of -$0.68, Slightly Beating Estimates
Kyverna Therapeutics (KYTX) reported third-quarter GAAP earnings per share of -$0.68, representing a $0.01 beat against analyst expectations. The company's financial results reflect its ongoing clinical development stage and current spending patterns. As of September 30, 2024, the company held $170.6 million in cash, cash equivalents, and marketable securities. This liquidity position, supplemented by available funds from an amended loan facility with Oxford Finance, is intended to support its ongoing operations and research initiatives.
Tickers: $KYTX
Topics: cash position earnings beat liquidity